With the global geopolitical sphere in flux at the moment following the US attacks on Iran, the folk at UBS have helpfully looked back at how the Australian market has fared in times of crisis.

Keep calm and carry on

Overall, they say, investors should have little to fear, with the local market tending to perform well in the months following disruptions.

As they wrote in a note to clients today:

Tracing back over 15 previous geopolitical shocks that have occurred over the last 50 years, we find that the impact on the Australian equity market is not much, with the market up 4%, 5% and 11% over the subsequent 3, 6 and 12 months respectively. In fact, with the exception of the first Gulf War, geopolitical shocks tend to have had no real lasting negative impact. It is also worth noting that Australia is a net exporter of Energy due to its large LNG export earnings. So higher energy prices would be a headwind to the consumer via petrol prices, but in theory the overall economy could be in a wealthier position.

Sectoral winners

So what about sector by sector? According to UBS, it’s clear that mining and energy companies tend to outperform in times of instability, while insurers underperform.

They added:

Right now miners map most neatly with a fundamental view we have held since late last year. That being that miners have not just outstanding earnings momentum at play, but benefit from the structural diversification out of the US, as well as investment flows rotating away from AI risks.

They have also moved industrial stocks to an overweight sector recommendation.

They added:

The sector not only screens best on our sector tracker screen, but showed a good story through results owing to solid (and stable) end demand in their Australian businesses. The sector is also positioned as a relative ‘safe haven’ for investors looking to detach themselves from global uncertainties. Real Estate moves underweight on rate concerns, whilst Banks move up to Neutral on the prospect of further earnings upgrades.

UBS has moved energy from an underweight rating to neutral, “to neutralise exposure to the likely blow up in oil and gas prices if the conflict is prolonged”.

UBS said overall the recent reporting season was strong, albeit with a few themes which caused disruption, such as the “AI rout”, as companies whose business models were potentially at risk of disruption were sold down.

UBS says some of these sell-offs “probably look overdone”.

The post How is global uncertainty likely to affect the Australian market: UBS appeared first on The Motley Fool Australia.

More reading

• 3 excellent Australian tech stocks to buy before they rebound
• Deep Yellow share price paused ahead of pending announcement
• Up 147% in a year, ASX All Ords gold stock jumping again today on new high-grade intercepts
• Why is BHP share price sinking today?
• One uranium stock to buy and one to sell, according to Macquarie

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Deep Yellow Ltd (ASX: DYL) share price has paused trading as the company awaits a further announcement, with investors watching closely.

What did Deep Yellow report?

• Pause in trading announced for Deep Yellow
• No specific earnings or operational figures provided in this announcement
• Further update from the company pending

What else do investors need to know?

Trading in Deep Yellow shares has been temporarily paused as the company prepares a further announcement to the market. ASX Listings Compliance made this request, with an official market notice issued on 5 March 2026.

Investors will need to wait for the pending update before trading resumes, and this may impact short-term trading activity. As always, investors should consider their own circumstances and seek further information when the update is released.

What’s next for Deep Yellow?

The next steps depend on the forthcoming announcement from Deep Yellow. Investors should keep an eye out for any updates that may impact the company’s outlook or operational plans.

It is important for shareholders to remain informed and review the company’s upcoming communications closely.

Deep Yellow share price snapshot

Over the past 12 months, Deep Yellow shares have risen 150%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 10% over the same period.

View Original Announcement

The post Deep Yellow share price paused ahead of pending announcement appeared first on The Motley Fool Australia.

More reading

• Lottery Corporation shakes up leadership with digital-first strategy
• A once-in-a-decade chance to get a 10%+ yield from ASX 200 income shares?
• Superloop surges past 250,000 Origin connections, triggers next milestone
• 5 things to watch on the ASX 200 on Thursday
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

ASX All Ords gold stock Aurum Resources Ltd (ASX: AUE) has been racing ahead of the All Ordinaries Index (ASX: XAO) this past year.

In early morning trade on Thursday, the Aurum Resources share price is up 3.5%, trading for 74 cents a share.

For some context, the All Ords is up 0.8% at this same time.

Taking a step back, the ASX All Ords gold stock has surged 146.7% over the past 12 months, compared to a 9.8% one-year gain posted by the benchmark index.

The African-focused miner has been benefiting from the surging gold price alongside its own exploration successes.

Here’s what’s happening today.

ASX All Ords gold stock lifts off on drill results

Investors are bidding up Aurum shares following the release of a promising exploration update.

The ASX All Ords gold stock reported hitting multiple broad, shallow, high-grade gold intercepts. This stems from Aurum’s ongoing 30,000 metre diamond drilling program at its Napie Gold Project, located in Cote d’Ivoire.

Management said the latest results, which focus on the Tchaga and Gogbala deposits, provide the final data ahead of the upcoming Napie Mineral Resource Estimate (MRE) update.

Top results from the Gogbala deposit include 19.0 metres at 5.16 grams of gold per tonne from 146.0 metres, including 14.0 metres at 6.76 g/t Au.

Top results from the Tchaga deposit were reported to be 18.9 metres at 2.59 g/t Au from 176.1 metres, including 5.9 metres at 7.33 g/t Au.

Looking ahead, the ASX All Ords gold stock plans 130,000 metres of diamond drilling in calendar year 2026, with 100,000 metres planned at its 3.3-million-ounce Boundiali project and 30,000 metres at the 870,000-ounce Napie project.

As at 31 December, Aurum Resources held $42.2 million in cash.

What did management say?

Commenting on the results helping boost the ASX All Ords gold stock today, Aurum managing director Caigen Wang said: “This latest round of step-back diamond drilling at Napie continues to deliver broad, shallow, open-pitable intercepts, confirming the system’s potential for substantial resource growth.”

Wang added:

Our objective is to build a substantial multi-asset gold business in Cote d’Ivoire. While our near-term focus is the development of our Boundiali Project, the scale and grade continuity we are seeing at Napie – following our acquisition of Mako – suggests that it too has the potential to grow into a second major production pillar.

Is it too late to buy this soaring ASX All Ords gold stock?

After already rocketing 147% over 12 months, is the ASX All Ords stock still a good buy today?

Very much so, according to the team at Canaccord Genuity.

The broker has a speculative buy rating on Aurum Resources, with a price target of $1.50 per share. That represents a potential upside of more than 102% from current levels.

The post Up 147% in a year, ASX All Ords gold stock jumping again today on new high-grade intercepts appeared first on The Motley Fool Australia.

More reading

• Up 172% in a year, why this surging ASX All Ords gold stock is forecast to more than double investors’ money again

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The BHP Group Ltd (ASX: BHP) share price is missing out on the market rebound on Thursday.

At the time of writing, the mining giant’s shares are down 2% to $54.55.

This compares unfavourably to a gain of 0.8% by the S&P/ASX 200 Index, which is recovering today after Wednesday’s broad market selloff.

So why are BHP shares moving lower while the wider market is pushing higher?

Why is the BHP share price underperforming?

Today’s decline has nothing to do with iron ore prices, copper demand, or a broker downgrade.

Instead, it appears to be the result of the Big Australian’s shares going ex-dividend today for its latest interim dividend.

When a company’s shares trade ex-dividend, it means the rights to the upcoming dividend have been settled.

As a result, investors who purchase the shares from today onwards will not be eligible to receive the payment. Instead, the dividend will be paid to the seller of the shares, even though they will no longer own them when the payment is made.

Because dividends form part of a company’s valuation, a share price will often fall by roughly the value of the dividend on the ex-dividend date.

After all, investors generally do not want to pay for something they will not receive.

The latest BHP dividend

Last month, BHP released its half-year results for FY 2026 and declared a fully franked interim dividend of 73 US cents per share.

This represents a very sizeable cash return of US$3.7 billion for shareholders and continues the mining giant’s long-standing approach of distributing a large portion of its profits through dividends.

Based on the BHP share price at yesterday’s close of $55.68 and current exchange rates, the interim dividend represents a dividend yield of roughly 1.85%.

That means a $20,000 investment in BHP shares would generate around $370 of income from this interim dividend alone.

When is the dividend being paid?

If you were holding BHP shares before the ex-dividend date, you will not have long to wait for the payment.

The mining giant plans to pay this interim dividend to eligible shareholders later this month on 26 March.

What’s next?

According to a note out of Morgans, its analysts expect a similar dividend in the second half.

This is expected to underpin a full-year dividend of approximately A$2.16 per share in FY 2026. It then expects a A$1.98 per share dividend in FY 2027.

Based on its current share price, this represents dividend yields of 4% and 3.6%, respectively.

The post Why is BHP share price sinking today? appeared first on The Motley Fool Australia.

More reading

• 5 Australian stocks to buy and hold for the next 5 years
• 5 things to watch on the ASX 200 on Thursday
• What’s next for the BHP share price?
• Want to receive the BHP, Rio Tinto, and Woodside dividends? Here’s what you need to do
• 3 must-own ASX blue-chip dividend stocks for Aussie investors

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The uranium market is on the cusp of entering a new “supercycle” according to some analysts, but that doesn’t mean all uranium mining companies are an automatic buy.

The team at Macquarie have looked at two Australian uranium companies and believes one’s looking good, while the other has some issues to work through.

Let’s have a look at what they’re saying.

Bannerman Energy Ltd (ASX: BMN)

This company is not a producer yet, but has recently made significant progress on funding for its Etango project in Namibia.

In mid-February, Bannerman announced that a Chinese company, the China National Nuclear Corporation, would invest up to US$321.5 million in the Etango project for a 42.75% stake.

Bannerman would then own 52.25% of the project with a Namibian organisation holding the remaining 5%.

The company said the funding would allow for the debt-free construction of the Etango mine, and CNNC had also agreed to buy 60% of the production from the mine.

Macquarie said in a research note to clients that CNNC was a strong partner for the project, given it already owned a majority stake in the Rossing uranium mine in Namibia and 25% of Paladin Energy Ltd (ASX: PDN)’s Langer Heinrich mine.

Macquarie said the deal substantially reduces equity dilution to finance the project, and added:

Etango Financial investment decision mid-year now looks a lot more certain, placing it at the front of the greenfield uranium project queue – something that customers should value as BMN markets the remaining 40% of the initial (production).

Macquarie has an outperform rating and a $5.60 price target on this ASX uranium share, compared with its current price of $4.38.

Boss Energy Ltd (ASX: BOE)

Boss Energy recently reported what it called a strong financial and operational result, chalking up a net loss of $7.9 million; however, this was largely due to the accounting treatment of inventory, while free cash flow was robust at $36.2 million.

The real story for investors is around what will happen longer term with the Honeymoon uranium mine, where the company said in mid-December that it had to throw away the assumptions under a previous feasibility study and start again.

On the upside, the company said there was a potential pathway forward for an alternative wide-spaced well design; however, it remained at concept stage at this point.

The company said there was the potential for lower costs and better production from the new design; however, more work remained to be done.

The team at Macquarie says this constitutes a major risk for investors.

As they said:

We still hold the view that Honeymoon will be challenging, and wide spacing trials carry risk. A complicated proposition; we believe investors should wait to see more definitive results from wider spaced leach trials first before making an investment decision.

Macquarie has a price target of $1.30 on this ASX uranium share, compared with $1.74 currently.

The post One uranium stock to buy and one to sell, according to Macquarie appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Bannerman, CBA, and Telstra shares
• Why Boss Energy, Lindian, Magellan, and New Hope shares are rising today
• Here are the top 10 ASX 200 shares today
• Top broker upgrades Boss Energy shares to a buy rating
• These are the 10 most shorted ASX shares

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Pro Medicus Ltd (ASX: PME) share price has suffered a 60% decline in the past six months, at the time of writing. For many years, I’ve considered Pro Medicus to be one of the best businesses in Australia.

However, it’s understandable why the market has sent it lower. The company was priced on expectations that its revenue and net profit were going to soar significantly in the coming years.

On a price/earnings (P/E) ratio basis, the Pro Medicus share price may have raced ahead of itself when it soared above $300.

However, at a much lower valuation, I think the business could be an appealing buy. After falling 60%, it could even be called a contrarian buy, though it does still trade on a high earnings multiple.

Quality growth continues

The ASX share market is normally forward-looking. By sending the Pro Medicus share price down so much, the market is suggesting the future is not as bright for the company.

But, investors are just speculating that the business will suffer from AI-produced competition. They are also assuming the business has no economic moat to fend off competition, despite its wonderful software offering, excellent sales team and powerful financials.

The business delivered a number of impressive numbers in the FY26 half-year result.

Revenue climbed 28.4% to $124.8 billion, the operating profit (EBIT) margin increased to 73% (up from 72%) and the underlying profit before tax climbed 29.7% to $90.7 million.

What other ASX share that’s the size of Pro Medicus (or larger) can point to that level of success?

It continues to win new contracts, sell additional modules to existing clients and it disclosed its pipeline remains “very strong”.

Based on the numbers and commentary, it seems the business is still well-positioned to deliver excellent profit growth. AI doesn’t seem to be affecting the company’s progress and it’s still winning contracts that can help push profit even higher.

The company’s quality is not in doubt, in my view.

The Pro Medicus share price valuation is now much better

Commsec’s projection suggests the business could generate earnings per share (EPS) of $1.42 in FY26 and $1.85 in FY27.

That means the company is now valued at 82x FY26’s estimated earnings and 63x FY27’s estimated earnings.

That’s not the lowest P/E ratio around, but it’s now dramatically lower. For any investor who has wanted to buy Pro Medicus shares, this is now a great chance to jump in.

Pro Medicus can continue to improve its software, possibly by using AI itself, and stay ahead of any potential challengers. I think the company’s future may now be underestimated by the market and therefore undervalued.

The post Is the Pro Medicus share price an opportunity too good to pass up? appeared first on The Motley Fool Australia.

More reading

• 3 excellent Australian tech stocks to buy before they rebound
• Beaten down: Are Cochlear, Pro Medicus or CSL shares a better buy right now?
• Here are the top 10 ASX 200 shares today
• $5,000 to invest? Here’s how I’d split it across the ASX
• The five worst performing ASX 200 stocks bought and held in February unmasked

Motley Fool contributor Tristan Harrison has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Lottery Corporation Ltd (ASX: TLC) shares are pushing higher on Thursday morning.

At the time of writing, the ASX 200 stock is up 1% to $5.46.

Why is this ASX 200 stock rising?

Investors have been buying the lottery company’s shares today after it announced a new operating model and changes to its executive leadership team.

The ASX 200 stock notes that these changes are designed to accelerate growth.

According to the release, Lottery Corporation has revealed a new organisational structure aimed at supporting the next stage of its strategy and helping it evolve further as a digital entertainment company.

Under the new model, Lottery Corporation will create three customer-facing business units. These are Lotteries, Digital, and Keno.

It notes that each will have a distinct strategic mandate and will report to a chief operating officer structure.

Management believes this will improve focus, accountability, and decision-making across the business.

The ASX 200 stock’s CEO, Wayne Pickup, said the company is well positioned but believes the new structure will help unlock further value. He commented:

We have a strong foundation and our strategy has served the Company well, but we can unlock more value. This new structure gives us the clarity and accountability to accelerate our evolution as a digital entertainment company, concentrate on local market growth and make faster, better decisions.

Leadership changes

Several leadership changes will accompany the new operating structure.

The release highlights that Callum Mulvihill will become chief operating officer of Lotteries, responsible for growing the company’s core lotteries portfolio across its retail network and digital wholesale partnerships.

Loren Somerville will take on the role of chief operating officer of Digital, with responsibility for driving digital lottery sales, improving app and web experiences, and exploring new opportunities in adjacent lottery entertainment categories.

Antony Moore will become chief operating officer of Keno, overseeing both venue-based and online Keno operations as the company looks to expand the product’s reach.

Alongside these customer-facing units, the company will also establish three enterprise service divisions covering Financial & Corporate Services, Strategy, and People & Brand.

The company’s chief financial officer Adam Newman will remain in his role, with expanded responsibilities including legal, risk, cyber and technology services.

When will the changes take effect?

The new operating model and leadership structure are expected to take effect from 1 July 2026, subject to regulatory approvals.

And based on its share price performance this morning, investors appear to be welcoming the announcement.

The post Guess which ASX 200 stock is pushing higher on big news appeared first on The Motley Fool Australia.

More reading

• Lottery Corporation shakes up leadership with digital-first strategy
• 5 ASX dividend shares to buy for income in 2026
• 3 strong ASX dividend stocks for retirees to buy
• 3 ASX dividend shares I would buy with $3,000
• 16 ASX shares going ex-dividend next week

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended The Lottery Corporation. The Motley Fool Australia has recommended The Lottery Corporation. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Three ASX healthcare giants have endured a very rough 12 months. 

At the time of writing: 

• CSL Ltd (ASX: CSL) are down almost 46% 
• Pro Medicus Ltd (ASX: PME) have fallen 55.72%
• Cochlear Ltd (ASX: COH).

These results have all contributed significantly to the softness of the broader ASX healthcare sector. 

The S&P/ASX 200 Health Care Index (ASX: XHJ) is down approximately 33% in the last 12 months. 

For context, the S&P/ASX 200 Index (ASX: XJO) is up 9.3% in that same span. 

What are brokers saying about these healthcare stocks?

These three companies are amongst the largest healthcare stocks by market cap.

This means it could be an opportunity to buy low, with long-term upside. 

Let’s see if there is any upside according to experts. 

CSL

In February, CSL reported total revenue of US$8.3 billion, down 4% while net profit fell 7% to $1.9 billion.

Messaging from management indicated this was a disappointing result, and investors seemed to agree. 

Sentiment around this healthcare giant seems to be mixed. 

The team at Fairmont Equities recently put a sell recommendation on CSL shares. 

Ord Minnett has a hold rating and $198.00 price tag. 

Meanwhile, UBS has a price target of $235 on CSL shares. 

CSL shares closed at $142.86 yesterday. 

Pro Medicus

Pro Medicus was amongst the worst performing ASX 200 stocks during February. 

It’s worth noting on the positive side however, is that three of the company’s directors have increased their existing stake by purchasing additional Pro Medicus shares. 

This can be a sign of confidence from management, which can positively influence investor sentiment. 

It now sits almost 48% lower than the start of 2026. 

The company appears to be another victim of AI disruption fears.

Pro Medicus closed trading yesterday at $116.19. 

However, 13 analysts ratings via TradingView place have an average 12 month target of $220.75. 

That’s almost 90% upside from current levels. 

Cochlear

Cochlear shares have also endured a rough year, particularly post earnings. 

It was dumped on results day on 17 February after missing expectations. 

The response from Morgans was a hold recommendation and 12-month share price target on Cochlear of $214.93.

The broker said the 1H26 result was softer than expected, with revenue, margins and profit negatively impacted mainly on longer than anticipated contracting for the newly launched Nucleus Nexa system (Nexa).

This target is approximately 15.66% higher than yesterday’s closing price of $185.83. 

The 15 analyst offering one year forecasts via TradingView have an average price target of $255.59 on Cochlear shares.

That would be approximately 37% upside.

The post Beaten down: Are Cochlear, Pro Medicus or CSL shares a better buy right now? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• $5,000 to invest? Here’s how I’d split it across the ASX
• How high does UBS think CSL shares will go?
• I’d listen to Warren Buffett and buy quality ASX shares at fair prices today
• The five worst performing ASX 200 stocks bought and held in February unmasked

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL, Cochlear, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Paladin Energy Ltd (ASX: PDN) boosted its revenue significantly in the first half of the year, which was good news for the company, but according to the analyst team at Shaw and Partners, the real story is the company’s growth plans across both Namibia and Canada.

Paladin reported revenue of US$138.3 million for the first six months of the year, up 79%, but posted a net loss of US$6.6 million driven by spending on ramping up production at its Langer Heinrich mine in Namibia.

The company had previously reported that fourth quarter production at Langer Heinrich jumped by 16% over the previous quarter to 1.23 million pounds.

Growth plans developing

Managing director Paul Hemburrow said when releasing the quarterly report that Langer Heinrich was performing well.

As global interest in nuclear energy continues to strengthen, I am delighted by our progress in ramping-up operations at Langer Heinrich Mine. The new level of production achieved during the quarter provides insight into the robust performance that can be achieved from this strategic uranium asset. Our site team’s goal is to continue delivering a consistent operational performance for the remainder of this financial year. The capability of our Canadian team is growing under the leadership of Dale Huffman as President Paladin Canada, with exploration and permitting workstreams advancing at PLS.  

PLS refers to the Patterson Lake South Project in the Athabasca region of Canada, which Paladin acquired in 2024.

The company’s website sates that it is a high-grade, near-surface uranium deposit at an advanced stage of development.

Top tier projects in focus

It’s the combination of the two projects – Langer Heinrich, and PLS – which has the Shaw team interested.

As they said in a research note to clients this week:

The combination of Langer Heinrich with Patterson Lake South has the potential to transform Paladin Energy into a 15 million pound per year uranium producer generating over US$2b of EBITDA per annum. At a 10x EBITDA multiple – that would make our $17.50 price target very conservative.  

Shaw said the PLS project currently has a mineral reserve of 93 million pounds, “and Paladin is aiming to bring it into production in 2031 at a rate of 9Mlb/yr over a 10 year mine-life”.

They added:

Paladin’s focus will shift to Patterson Lake South, its tier 1 growth project in the Athabasca Basin, post completion of a successful ramp-up of Langer Heinrich to full capacity in mid-2026. The Paladin share price has re-rated as the market recognised that the temporary commissioning issues at Langer Heinrich, were temporary. The next phase of Paladin outperformance will be driven by a strengthening uranium market, and by the market recognising the valuation upside in PLS. Paladin is one of our preferred exposures to the coming uranium market super-cycle.

The Shaw price target of $17.50 compares with the current price for Paladin Energy shares of $12.58, representing potential upside of 39.1%.

Paladin was valued at $5.65 billion at the close of trade on Wednesday.

The post How much upside is there in Paladin Energy shares? appeared first on The Motley Fool Australia.

More reading

• Why the Paladin share price is sinking 9% today
• Which ASX uranium stock is the smarter buy: Nexgen Energy or Paladin Energy?
• Here are the top 10 ASX 200 shares today
• Paladin share price jumps after major Canadian project approval
• Paladin share price on ice pending major announcement

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Finding S&P/ASX 200 Index (ASX: XJO) shares you can confidently tuck away for a decade isn’t about chasing hype. It’s about backing quality businesses with durable competitive advantages, global growth runways, and management teams that execute.

Two ASX 200 shares that tick those boxes are ResMed Inc (ASX: RMD) and Life360 Inc (ASX: 360). Both operate in structurally growing markets. Both ASX 200 shares have delivered strong long-term share price gains despite bouts of volatility. And both continue to attract positive analyst attention.

ResMed: global healthcare powerhouse

This ASX 200 share develops cloud-connected medical devices and software for the treatment of sleep apnoea, chronic obstructive pulmonary disease, and other respiratory conditions. ResMed’s devices and digital health ecosystem generate recurring revenue from masks, consumables, and monitoring software.

ResMed has long been a market darling. While the healthcare share price has seen swings over the past years, in the past 10 years the company has gained 365% in value to $52 billion. After reaching an all-time high in August of $45.25, ResMed has tumbled almost 20% to $36.34 at the time of writing.

However, the company’s strengths are clear. The ASX 200 share holds a dominant position in sleep therapy, benefits from an ageing global population, and leverages data-driven technology to enhance patient outcomes. Its software platforms also deepen relationships with healthcare providers, creating high switching costs.

Recent earnings results showed continued revenue growth and margin resilience, with strong demand across its core sleep and respiratory segments. Management has highlighted ongoing product innovation and expanding digital integration as key drivers.

Risks include regulatory changes, competitive pressure, and currency movements given its global footprint. Concerns about new obesity drugs reducing sleep apnoea incidence have also weighed on sentiment at times.

Still, many analysts remain constructive on the Aussie stock. TradingView data show that most market watchers see the ASX 200 share as a buy. They have set an average 12-month price target of $43.64, while the more optimistic target peaks at $52.48. This suggests to a 44% upside at current price levels.

Life360: scaling a digital ecosystem

Life360, by contrast, has been a higher-volatility growth story. The ASX 200 shares have surged dramatically over the past five years, rising more than 600% at one stage. But they have also experienced sharp pullbacks. In the past 6 months the tech stock has dropped 55% to $20.38 at the time of writing.

Life360 operates a global digital safety platform focused on families. It offers location sharing, crash detection, roadside assistance, and identity protection services, primarily through subscription plans. The company has steadily grown monthly active users toward the 100 million mark, providing a strong funnel for paid conversions.

Its key strength lies in monetisation. Life360 continues converting free users into paying subscribers while expanding into higher-margin advertising through acquisitions and integrations.

Latest results showed continued revenue growth and rising subscription numbers, alongside improving profitability metrics. Management remains focused on balancing user growth with monetisation and cost discipline.

Risks include reliance on continued subscriber growth, privacy scrutiny around data usage, and competition from larger tech players. The stock also pays no dividend, reflecting its growth-first strategy.

Analyst sentiment remains broadly positive. Recent broker updates reiterate buy ratings, with price targets implying meaningful upside. Bell Potter just retained their buy rating with a trimmed price target of $40.00. This points to an upside of nearly 100% at current levels.

The post 2 of the best Aussie ASX 200 shares to buy and hold for 10 years appeared first on The Motley Fool Australia.

More reading

• 5 Australian stocks to buy and hold for the next 5 years
• Life360 shares crashed 18% this week: Is this a once-in-a-lifetime buying opportunity?
• Top brokers name 3 ASX shares to buy today
• Why EOS, GenusPlus, Life360, and WIA Gold shares are rising today
• 3 ASX growth shares you’ll wish you’d bought at these cheap prices

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360 and ResMed. The Motley Fool Australia has positions in and has recommended Life360 and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.